At the core of our work is Induced Native Phage Therapy (INPT)—an advancement upon over a century of established bacteriophage science. The INPT platform is designed to activate specific monovalent and/or polyvalent phages from within the tens of thousands of beneficial phage populations always inhabiting the human body.

There is an obvious global need for effective solutions. Rather than introduce new chemicals, externally sourced phages (as in conventional phage therapy), or broad-spectrum pharmaceutical antimicrobials, INPT appears to turn specific native phages from lysogenic (dormant) phages into lytic activated phages which can more directly and rapidly eliminate the targeted infections. These phages are part of the natural human microbiome, and collectively are known as the phageome. The phageome has long been unappreciated, yet it has made a global resurgence and is now gaining recognition for its role in maintaining microbial equilibrium, in partnership with the immune system.

Each INPT formula is engineered to deliver subtle yet scientifically validated informational signals—not active compounds—via oral nanoparticle suspensions that are non-toxic, non-allergenic, and compatible with most health protocols.

The INPT formulas, collectively called Inducen formulas, are named according to the targeted issues, such as Inducen-RES for respiratory tract issues and Inducen-LD/RF for Borrelia and tickborne diseases.

Inducen formulas do not require adaption to the patient but are designed to act universally and precisely, activating only those native phage populations common to the microbes being targeted by those phages.